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Abstract
Background Sphincter-preserving procedures for the
treatment of transsphincteric fistulas fail in at least one out
of every three patients. It has been suggested that failure is
due to ongoing disease in the remaining fistula tract.
Cytokines play an important role in inflammation. At
present, biologicals targeting cytokines are available.
Therefore, detection and identification of cytokines in anal
fistulas might have implications for future treatment
modalities. The objective of the present study was to assess
local production of a selected panel of cytokines in anal
fistulas, including pro-inflammatory interleukin (IL)-1b
and tumor necrosis factor a (TNF-a).
Methods Fistula tract tissue was obtained from 27 patients
with a transsphincteric fistula of cryptoglandular origin
who underwent flap repair, ligation of the intersphincteric
fistula tract or a combination of both procedures. Patients
with a rectovaginal fistula or a fistula due to Crohn’s dis-
ease were excluded. Frozen tissue samples were sectioned
and stained using advanced immuno-enzyme staining
methods for detection of selected cytokines, IL-1b, IL-8,
IL-10, IL-12p40, IL-17A, IL-18, IL-36 and TNF-a. The
presence and frequencies of cytokine-producing cells in
samples were quantitated.
Results The key finding was abundant expression of IL-1b
in 93 % of the anal fistulas. Frequencies of IL-1b-pro-
ducing cells were highest ([50 positive stained cells) in
7 % of the anal fistulas. Also, cytokines IL-8, IL-12p40 and
TNF-a were present in respectively 70, 33 and 30 % of the
anal fistulas.
Conclusions IL-1b is expressed in the large majority of
cryptoglandular anal fistulas, as well as several other pro-
inflammatory cytokines.
Keywords Perianal fistulas  Platelet-rich plasma  Auto-
inflammatory  Immunology  Bacteria  Microbiota
Introduction
In a previous study, conducted in patients with a persistent
anal fistula after flap repair, we observed complete healing
of the flap, except at the site of the original internal fistula
opening [1]. This observation and the fact that there are,
most likely, no factors predisposing to failure suggest that
persistence of anal fistulas is caused by ongoing inflam-
mation in the remaining fistula tract. A recent study, con-
ducted at our institution, revealed that the majority of anal
fistulas are lined with granulation tissue (75 %), which is
suggestive of an inflammatory response [2].
Since local bacterial replication might be an inflamma-
tory factor, we performed another study [3]. A paucity of
bacteria was observed in the fistula tracts. Bacterial species
were bowel derived, skin derived or a combination of both.
No mycobacterium species were identified. Therefore, it
seems unlikely that bacterial infection plays a major role in
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persistence of fistula after surgery. These results were
recently confirmed by Tozer et al. [4].
In the same study, we detected pro-inflammatory pep-
tidoglycan in the majority of anal fistulas [3]. Peptidogly-
can is a major component of the bacterial cell wall of both
Gram-positive and Gram-negative species, providing
structural strength and allowing bacteria to resist osmotic
pressure. Peptidoglycan has potent pro-inflammatory
properties and stimulates processing and secretion of the
cytokine interleukin (IL)-1b [5, 6]. This suggests that even
in the absence of local bacterial replication, bacterial
components promote chronic inflammation. Studies on the
pathogenesis of different chronic inflammatory diseases,
such as Crohn’s disease, show that peptidoglycan is a
powerful effector-stimulating inflammation [7, 8].
Cytokines play an important role in inflammation.
Tumor necrosis factor (TNF)-a, IL-1b and other cytokines
promote inflammatory responses that cause many of the
clinical problems associated with immune-mediated dis-
eases, such as rheumatoid arthritis, hidradenitis suppura-
tiva, ulcerative colitis and Crohn’s disease [9–12].
Biologicals targeting cytokines, such as anti-TNF-a and
IL-1 receptor antagonist, are used in various diseases and
clinical trials [13]. An overview of these agents is pre-
sented in Table 1, focusing on cytokines addressed in the
current study. The question is whether one of these agents
might play a role as adjunct in the treatment of anal fistulas.
The objective of the present observational study was to
detect and to identify cytokines in anal fistulas of cryp-
toglandular origin.
Materials and methods
Study design
Anal fistula tissue was obtained from 27 patients with a
transsphincteric fistula of cryptoglandular origin that
underwent transanal advancement flap repair (TAFR),
ligation of the intersphincteric fistula tract (LIFT) or a
combination of both procedures at the Division of Colon
and Rectal Surgery, Erasmus MC, University Medical
Center. Prior to the procedure, patients underwent endoanal
magnetic resonance imaging to visualize the course of the
fistula tract and to determine the presence and location of
associated abscesses. Patients with a rectovaginal fistula
and/or a fistula due to Crohn’s disease were excluded from
this study. None of the patients had hepatitis B and/or
human immunodeficiency virus (HIV) infection at the time
of surgery. None of the patients used antibiotics and/or
immunomodulatory drugs prior to surgery. Baseline patient
and fistula characteristics are presented in Table 2. All
patients provided informed consent meeting the standards
set by the hospital’s institutional review board. All opera-
tions were performed in a time period of 3 years by one
surgeon and several colorectal surgery fellows. Patients
were treated in a day-care setting.
Operative techniques
We have described our techniques of TAFR and LIFT
earlier in detail [18].
Sample collection
The external fistula opening was enlarged, and the fistula
tract was excised as far as possible until the outer border of
the external anal sphincter. Immediately after excision, the
fistula tract was frozen using dry ice and transported to the
laboratory for cryopreservation. Excised tissue was cry-
opreserved in liquid nitrogen and subsequently stored at
-80 C for processing. The value of samples from healthy
controls or patients with other diseases as reference groups
has been considered. However, the only possibility to
obtain healthy anal tissue (including anal glands) from
patients is during major surgery of this specific part of the
body. Indications for these types of surgery are Crohn’s
disease or colorectal cancer. These diseases would cer-
tainly bias any findings as they are associated with
increased expression of cytokines [11, 19]. Also, the
potential value of samples from deceased patients without
colorectal diseases as reference groups has been consid-
ered. However, we reasoned that any cause of death and
death itself might probably bias any findings. Therefore,
we have decided to use no reference group.
In situ analysis of cytokine-producing cells
Frozen tissue samples were sectioned and stained using
advanced immuno-enzyme staining methods for detection
of selected cytokines IL-1b, IL-8, IL-10, IL-12p40, IL-
17A, IL-18, IL-36 and TNF-a. This selection of cytokines
was designed based on current concepts of tissue inflam-
mation versus inflammation control (e.g., IL-10) and the
availability of clinically approved biologicals (see
Table 1). In short, frozen sections of 6 lm in thickness
were dried overnight in a humidified box before getting
fixed with freshly prepared acetone containing 0.02 % of
hydrogen peroxide to inhibit endogenous peroxidase
activity by cells in the tissue (e.g., granulocytes) for
10 min. Histochemical revelation of endogenous peroxi-
dase with 4-chloro-1-naphthol was performed, resulting in
a dense blue-black precipitate. After this, the sections were
incubated overnight with primary antibodies at previously
determined optimal dilutions at 4 C. The following com-
mercially available antibodies were used: antihuman IL-1b
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(clone 8516.31, R&D Systems, Minneapolis, MN, USA),
antihuman IL-8 (clone G265-8, BD Biosciences Pharmin-
gen, San Jose, CA, USA), antihuman IL-10 (clone JES3-
12G8, BD Biosciences Pharmingen, San Jose, CA, USA),
antihuman IL-12p40 (clone C8.6, BD Biosciences
Pharmingen, San Jose, CA, USA), antihuman IL-17A
(clone e B 1064 CAP, eBioscience Inc., San Diego, CA,
USA), antihuman IL-18 (rabbit IgG, Thermo Scientific,
Rockford, IL, USA), antihuman IL-36 (clone 3A12,
Abcam, Cambridge, MA, USA) and antihuman TNF-a
(clone 61E7, U-CyTech Biosciences, Utrecht, The
Netherlands). Secondary enzyme-labeled antibodies were
applied and incubated at room temperature. Between
incubations the slides were rinsed twice in phosphate-
Table 1 Summary of cytokines assessed and therapeutic options
Cytokine Main functions Therapeutic molecules (generic name of
biologicala)
Main (potential) clinical
applications
IL-1b Inflammatory response to infection. Mediates
fever and promotes formation of acute
phase proteins by the liver. Activation of T
and B lymphocytes. Elevates adhesion
molecules on endothelium. Induces other
cytokines such as IL-6. Resembles TNF-a
in its inflammatory properties
Anakinra (IL-1 receptor antagonist);
rilonacept (IL-1 receptor fusion protein);
canakinumab (anti-IL-b mab)
RA, CAPS such as Muckle–Wells
syndrome (MWS) and familial
cold auto-inflammatory
syndrome (FCAIS)
IL-8 alias
CXCL8
Mediator of innate immune responses.
Induces chemotaxis of T cells and
neutrophilic granulocytes. Promotes
phagocytosis and angiogenesis
Limited Spectrum of (auto)inflammatory
diseases
IL-10 Anti-inflammatory. Inhibits production of
cytokines by many cell types. Inhibits
activation and effector functions of T cells,
monocytes and macrophages
Limited, e.g., Tenovil (recombinant IL-10) Spectrum of (auto)inflammatory
diseases
IL-12p40 Differentiation of naive T cells into T helper 1
cells. Induction of IFN-c in NK cells and T
cells. Growth factor for activated
CD4 ? and CD8 ? T lymphocytes and NK
cells, and enhancement of their function
Ustekinumab (mab against shared p40 subunit
of IL-12 and IL-23); briakinumab (mab
against shared p40 subunit of IL-12 and IL-
23)
Psoriasis, CD
IL-17A Central to induction and maintenance of pro-
inflammatory responses. Induces other
inflammatory cytokines and mediators,
notably chemoattractants including those
for neutrophilic granulocytes. IL-17A is
critical to function of the Th17 subset of
CD4 ? lymphocytes
Secukinumab (mab against IL-17A);
ixekizumab (mab against IL-17A);
brodalumab (mab against IL-17 receptor)
Psoriasis, RA, AS, RRMS
IL-18
(IL-1
family)
Induces cell-mediated immunity to
intracellular pathogens. Induces IFN-c, and
other cytokines and chemokines
Limited Spectrum of (auto)inflammatory
diseases
IL-36
(IL-1
family)
Acts directly on naive T cells, enhancing
proliferation and IL-2 production.
Stimulates Th1 responses. Acts on dendritic
cells. Appears to be especially expressed
and functional in the skin
Limited Spectrum of (auto)inflammatory
diseases
TNF-a Participates in inflammation, wound healing
and remodeling of tissue. Induces apoptosis,
other cytokines and inflammation.
Facilitates leukocyte recruitment, induces
angiogenesis and promotes fibroblast
proliferation. Induces expression of
adhesion molecules on vascular
endothelium
Infliximab (anti-TNF mab); adalimumab
(anti-TNF mab); golimumab (anti-TNF
mab); etanercept (soluble receptor for
TNF); certolizumab (anti-TNF mab)
RA, CD, UC, AS, PsA, JIA,
Psoriasis, HS
AS ankylosing spondylitis, CAPS cryopyrin-associated periodic syndromes, CD Crohn’s disease, HS hidradenitis suppurativa, IL interleukin, JIA
juvenile idiopathic arthritis, mab monoclonal antibody, NK natural killer, PsA psoriatic arthritis, RA rheumatoid arthritis, RRMS relapsing
remitting multiple sclerosis, TNF tumor necrosis factor, UC ulcerative colitis [14–17]
a Nomenclature of biologicals includes: -cept for receptor, -ki(n) for interleukin, -mab for monoclonal antibody, -ra for receptor antagonist, -u
for human, -zu for humanized
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buffered saline/0.05 % Tween 20. Histochemical revela-
tion of horseradish peroxidase activity was performed
using aminoethyl carbazole (AEC, Sigma-Aldrich, St.
Louis, MO, USA) for a bright red translucent staining.
Finally, sections were counterstained with hematoxylin and
mounted in Kaiser’s glycerin gelatin with a cover slip.
Sections of reactive human tonsils were used as internal
positive control tissue since they contain numerous
leukocytes producing a variety of cytokines. Staining
controls were done by omission of the primary antibody
and by isotype- and subclass-matched negative control
antibodies.
Quantitation of cytokine-producing cells
In order to interpret the presence and frequencies of cyto-
kine-producing cells, the number of positive stained cells in
the fistula samples was scored from zero to four: zero for
no stained cells, one for 1–5 stained cells, two for 6–20
stained cells, three for 21–50 stained cells and four for[50
stained cells. All sections were evaluated by two inde-
pendent observers.
Statistical analysis
Continuous data are presented as mean values with stan-
dard deviation. Categorical data are presented as frequen-
cies or percentages. Data were analyzed by use of SPSS-
IBM software version 20.0 for Windows (SPSS, Chi-
cago, IL, USA).
Results
Anal fistula samples were obtained from 27 patients with a
transsphincteric fistula of cryptoglandular origin during
surgery. Of these, 13 patients (48 %) underwent flap repair,
6 patients (22 %) underwent ligation of the intersphincteric
fistula tract (LIFT) and 8 patients (30 %) underwent a
combination of both procedures. The majority of the
patients had undergone a previous attempt at repair (67 %).
Based on available information, half of the patients con-
sumed alcohol and one-third of the patients smoked.
Baseline patient and fistula characteristics are presented in
Table 2. The presence and frequencies of cytokine-pro-
ducing cells in anal fistula samples were evaluated using a
pathology scoring system. These findings are presented in
Table 3. In the positive control tissue, reactive human
tonsils from children, cells producing all cytokines were
detected in varying numbers, as predicted. This confirms
the anticipated reactivity of the antibodies used and their
suitability for detection of cytokines in frozen tissue. In
93 % of the fistula samples, the prominent pro-inflamma-
tory cytokine IL-1b was present. Frequencies of IL-1b-
producing cells were highest ([50 positive stained cells) in
7 % of the fistula samples (Fig. 1). The cytokines IL-8, IL-
12p40 and TNF-a were present in 70, 33 and 30 %,
respectively, of the fistula samples (Fig. 1). IL-10, IL-17A,
IL-18 and IL-36 could not be detected. No significance
difference in cytokine expression was detected between
patients with a persistent fistula after previous attempts at
repair and those presenting with a new fistula. However,
most likely the sample sizes are too small to detect any
differences between the groups.
Discussion
The key finding of the present study was the abundant
expression of pro-inflammatory cytokine IL-1b in 93 % of
the anal fistulas. Also, the cytokines IL-8, IL-12p40 and
TNF-a were expressed in a high number of anal fistulas
(Table 3).
Limitations of this study are the lack of a control or
reference group, the small number of patients, lack of
additional staining for identification of cell types that
Table 2 Baseline patient and fistula characteristics (N = 27)
Patient and/or fistula characteristic N
Age at surgery (years) 46.2 ± 10.5
Sex (male) 15 (55.6)
Fistula type
HTS 22 (81.5)
LTS 5 (18.5)
Previous attempts at repair
0 8 (29.6)
C1 18 (66.7)
Location internal fistula openinga
Anterior 10 (37.0)
Posterior 15 (55.6)
Lateral 1 (3.7)
Location external fistula opening
Anterior 0 (0)
Posterior 4 (14.8)
Lateral 23 (85.2)
Type of operative technique
TAFR 13 (48.2)
LIFT 6 (22.2)
TAFR and LIFT 8 (29.6)
Categorical variables are presented as numbers (%). Continuous
values are expressed as mean ± SD
HTS high transsphincteric fistula, LTS low transsphincteric fistula,
TAFR transanal advancement flap repair, LIFT ligation of inter-
sphincteric fistula tract
a The internal fistula opening was not identified in one patient
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produce cytokines and a potential selection bias caused by
the role of our institution as tertiary referral center.
Strengths of the study are the comprehensive panel of
cytokines studied and the homogeneity of the patient
group.
IL-1 is a central mediator of innate immunity, inflam-
mation and fever. As a highly active pro-inflammatory
cytokine, it contributes to lowering pain thresholds and to
tissue damage. IL-1b can be produced by many different
cell types, with a prominent role of monocytes and mac-
rophages [20]. The stimulus can be microbial products,
cytokines and even IL-1b itself [21]. Self-induction by IL-1
is part of the mechanism of auto-inflammation [12]. The
IL-1b precursor is inactive within the cell, and biologically
active IL-1b is produced by inflammasomes that cleave
pro-IL-1b using caspase-1.
Based on our previous study, it seems likely that
peptidoglycan is a one of the potential stimuli for the
expression of IL-1b in anal fistulas. Peptidoglycan
induces inflammasome NLRP3-mediated caspase-1
activation and thereby processing and secretion of IL-
1b. This concept is supported by the presence of
Table 3 Presence and frequencies of cytokine-producing cells in anal fistulas (N = 27)
Cytokine N (%) No stained cells 1–5 Stained cells 6–20 Stained cells 21–50 Stained cells [50 Stained cells
IL-1b 25 (92.6) 2 (7.4) 4 (14.8) 12 (44.4) 7 (26.0) 2 (7.4)
IL-8 19 (70.4) 8 (29.7) 4 (14.8) 6 (22.2) 5 (18.5) 4 (14.8)
IL-10 0 (0) 27 (100) 0 (0) 0 (0) 0 (0) 0 (0)
IL-12p40 9 (33.3) 18 (66.7) 1 (3.7) 7 (25.9) 1 (3.7) 0 (0)
IL-17A 0 (0) 27 (100) 0 (0) 0 (0) 0 (0) 0 (0)
IL-18 0 (0) 27 (100) 0 (0) 0 (0) 0 (0) 0 (0)
IL-36 0 (0) 27 (100) 0 (0) 0 (0) 0 (0) 0 (0)
TNF-a 8 (29.6) 19 (70.4) 3 (11.1) 4 (14.8) 1 (3.7) 0 (0)
Variables are presented as numbers (%)
IL interleukin, TNF tumor necrosis factor
Fig. 1 IL-1b and IL-8 in anal fistula samples. IL-1b and IL-8 are
expressed by cells within infiltrates of the anal fistula tissue. The
presence of IL-1b (red) and IL-8 (red) was detected by specific
antibodies. IL-1b is presented in the a (magnification 1009) and
b (magnification 2009). IL-8 is presented in the c (magnification
1009) and d (magnification 4009)
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peptidoglycan in 90 % of cryptoglandular anal fistulas
[3]. Self-induction by IL-1 may also be involved.
Overall, our findings suggest that cytokines contribute to
the inflammatory process in cryptoglandular anal fistulas.
Flap repair has been advocated as the treatment of choice
for high transsphincteric anal fistulas and enables healing in
two of every three patients [22, 23]. A pilot study by Ver-
hagen et al. showed that flap repair with additional injection
of platelet-rich plasma (PRP) in the anal fistula tract
increases the healing rate to 90 % [24].A second studywith a
longer duration of follow-up confirmed these promising
results [25]. According to the authors, PRP improves wound
healing and may therefore improve the closure rate of anal
fistulas. PRP has also anti-inflammatory potentials. Kim
et al. [26] showed that PRP is able to suppress expression of
degrading enzymes andmediators induced byTNF-a and IL-
1b. It seems likely that this mode of action also contributes to
the higher healing rate after flap repair. Currently, three IL-1
antagonists (anakinra, rilonacept and canakinumab) target-
ing IL-1b are approved for treatment of various diseases
(Table 1). Studies on IL-1 antagonists targeting a broad
spectrum of new indications, such as hidradenitis suppura-
tiva, show promising results [27].
Conclusions
Pro-inflammatory IL-1b is expressed in the large majority of
cryptoglandular anal fistulas. The clinical value of these
findings must be further studied before we can proceed to
apply adjunct treatment of anal fistulas by targeting cytokines.
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